Clinical trial results:
A Phase 3, Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER (Open-Label Extension)

Summary

EudraCT number	2011-003478-98
Trial protocol	SE NL HU GR DE DK CZ
Global end of trial date	12 August 2016

Results information

Result version number	v2 (current)
This version publication date	21 September 2017
First version publication date	20 August 2017
Version creation reason	• Correction of full data set One time point in the time frame for primary endpoint 4 corrected (from Week 201 to Week 204).

Trial information

Trial identification

Sponsor protocol code	M12-555

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01635764
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	AbbVie Deutschland GmbH & Co.
Sponsor organisation address	AbbVie House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, United Kingdom, SL6-4UB
Public contact	Global Medical Services, AbbVie, 001 800-633-9110,
Scientific contact	Dawn Carlson, MD, AbbVie, dawn.carlson@abbvie.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	12 August 2016
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	12 August 2016
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The purpose of this study to evaluate the long term safety, tolerability and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa (HS).

Protection of trial subjects:

Subject read and understood the information provided about the study and gave written permission

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	12 April 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 61
Country: Number of subjects enrolled	Canada: 53
Country: Number of subjects enrolled	Czech Republic: 28
Country: Number of subjects enrolled	Denmark: 13
Country: Number of subjects enrolled	France: 37
Country: Number of subjects enrolled	Germany: 44
Country: Number of subjects enrolled	Greece: 39
Country: Number of subjects enrolled	Hungary: 13
Country: Number of subjects enrolled	Netherlands: 16
Country: Number of subjects enrolled	Sweden: 2
Country: Number of subjects enrolled	Switzerland: 16
Country: Number of subjects enrolled	Turkey: 2
Country: Number of subjects enrolled	United States: 184
Worldwide total number of subjects	508
EEA total number of subjects	192

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37	0

wk	
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	502
From 65 to 84 years	6
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Subjects were evaluated for entry into Study M12-555 at the final study visit of the prior Phase 3 study in which they participated. Therefore, the Study M12-555 Baseline (Week 0) visit and administration of the first dose of study drug in Study M12-555 was performed on the same day as the final or last visit of the prior Phase 3 study.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Adalimumab Every Week

Arm description:

Adalimumab 40 mg every week.

Arm type	Experimental
Investigational medicinal product name	adalimumab
Investigational medicinal product code	
Other name	Humira
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Adalimumab pre-filled syringe, administered by subcutaneous injection

Number of subjects in period 1	Adalimumab Every Week
Started	508
Completed	235
Not completed	273
Exceed Protocol-specified Interventions	2
Not specified	28
Adverse event	46
Withdrew consent	67
Lost to follow-up	53
Lack of efficacy	76
Protocol deviation	1

Baseline characteristics

Reporting groups	
Reporting group title	Adalimumab Every Week
Reporting group description:	
Adalimumab 40 mg every week.	

Reporting group values	Adalimumab Every Week	Total	
Number of subjects	508	508	
Age categorical			
Units: Subjects			
Age continuous			
Baseline characteristics provided by reporting groups defined by treatment received in prior HS study plus treatment received in M12-555.			
Units: years			
arithmetic mean	36.8		
standard deviation	± 11.35	-	
Gender categorical			
Baseline characteristics provided by reporting groups defined by treatment received in prior HS study plus treatment received in M12-555.			
Units: Subjects			
Female	328	328	
Male	180	180	

Subject analysis sets	
Subject analysis set title	EW/EW/EW
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
All participants who received adalimumab 40 mg every week (EW) in both Period A and Period B of the prior Phase 3 studies.	
Subject analysis set title	EW/EOW/EW
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
All participants who received adalimumab 40 mg every week (EW) in Period A and 40 mg every other week (EOW) in Period B in the prior Phase 3 studies.	
Subject analysis set title	EW/PBO/EW
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
All participants who received adalimumab 40 mg every week (EW) in Period A and placebo in Period B in the prior Phase 3 studies.	
Subject analysis set title	PBO/EW/EW
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
All participants who received placebo in Period A and adalimumab 40 mg every week (EW) in Period B in prior phase 3 study M11-313.	
Subject analysis set title	PBO/PBO/EW
Subject analysis set type	Intention-to-treat

Subject analysis set description:

All participants who received placebo in both Period A and Period B in prior phase 3 study M11-810.

Reporting group values	EW/EW/EW	EW/EOW/EW	EW/PBO/EW
Number of subjects	88	90	92
Age categorical			
Units: Subjects			
Age continuous			
Baseline characteristics provided by reporting groups defined by treatment received in prior HS study plus treatment received in M12-555.			
Units: years			
arithmetic mean	35.5	36.1	36.5
standard deviation	± 10.27	± 10.5	± 11.06
Gender categorical			
Baseline characteristics provided by reporting groups defined by treatment received in prior HS study plus treatment received in M12-555.			
Units: Subjects			
Female	56	60	50
Male	32	30	42

Reporting group values	PBO/EW/EW	PBO/PBO/EW	
Number of subjects	115	123	
Age categorical			
Units: Subjects			
Age continuous			
Baseline characteristics provided by reporting groups defined by treatment received in prior HS study plus treatment received in M12-555.			
Units: years			
arithmetic mean	38.5	37	
standard deviation	± 11.92	± 12.28	
Gender categorical			
Baseline characteristics provided by reporting groups defined by treatment received in prior HS study plus treatment received in M12-555.			
Units: Subjects			
Female	79	83	
Male	36	40	

End points

End points reporting groups

Reporting group title	Adalimumab Every Week
Reporting group description: Adalimumab 40 mg every week.	
Subject analysis set title	EW/EW/EW
Subject analysis set type	Intention-to-treat
Subject analysis set description: All participants who received adalimumab 40 mg every week (EW) in both Period A and Period B of the prior Phase 3 studies.	
Subject analysis set title	EW/EOW/EW
Subject analysis set type	Intention-to-treat
Subject analysis set description: All participants who received adalimumab 40 mg every week (EW) in Period A and 40 mg every other week (EOW) in Period B in the prior Phase 3 studies.	
Subject analysis set title	EW/PBO/EW
Subject analysis set type	Intention-to-treat
Subject analysis set description: All participants who received adalimumab 40 mg every week (EW) in Period A and placebo in Period B in the prior Phase 3 studies.	
Subject analysis set title	PBO/EW/EW
Subject analysis set type	Intention-to-treat
Subject analysis set description: All participants who received placebo in Period A and adalimumab 40 mg every week (EW) in Period B in prior phase 3 study M11-313.	
Subject analysis set title	PBO/PBO/EW
Subject analysis set type	Intention-to-treat
Subject analysis set description: All participants who received placebo in both Period A and Period B in prior phase 3 study M11-810.	

Primary: Percentage of Participants in the EW/EW/EW, EW/EOW/EW, and EW/PBO/EW Analysis Populations Achieving Clinical Response Per Hidradenitis Suppurativa Clinical Response (HiSCR) at Each Visit

End point title	Percentage of Participants in the EW/EW/EW, EW/EOW/EW, and EW/PBO/EW Analysis Populations Achieving Clinical Response Per Hidradenitis Suppurativa Clinical Response (HiSCR) at Each Visit[1]
End point description: Clinical response per HiSCR defined as percent reduction from baseline of the prior phase 3 study in the abscess and inflammatory nodule ≥ 50% (AN50) with no increase in the abscess count and no increase in the draining fistula count. Last Observation Carried Forward (LOCF): The last completed evaluation from the previous visit was carried forward to impute missing data at later visits. n=number of participants at given time point.	
End point type	Primary
End point timeframe: Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive data were summarized for this endpoint per protocol.

End point values	EW/EW/EW	EW/EOW/EW	EW/PBO/EW	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	88[2]	90[3]	92[4]	
Units: percentage of particpants				
number (not applicable)				
Week 2 (n=88,88,91)	34.1	39.8	34.1	
Week 4 (n=88,90,92)	38.6	41.1	40.2	
Week 8 (n=88,90,92)	51.1	48.9	47.8	
Week 12 (n=88,90,92)	52.3	55.6	51.1	
Week 16 (n=88,90,92)	50	56.7	45.7	
Week 20 (n=88,90,92)	56.8	45.6	45.7	
Week 24 (n=88,90,92)	48.9	47.8	42.4	
Week 36 (n=88,90,92)	62.5	54.4	52.2	
Week 48 (n=88,90,92)	58	55.6	58.7	
Week 60 (n=88,90,92)	62.5	57.8	58.7	
Week 72 (n=88,90,92)	59.1	61.1	53.3	
Week 84 (n=88,90,92)	56.8	56.7	55.4	
Week 96 (n=88,90,92)	56.8	54.4	53.3	
Week 108 (n=88,90,92)	60.2	56.7	53.3	
Week 120 (n=88,90,92)	56.8	52.2	45.7	
Week 132 (n=88,90,92)	52.3	52.2	50	
Week 144 (n=88,90,92)	51.1	54.4	52.2	
Week 156 (n=88,90,92)	48.9	52.2	50	
Week 168 (n=88,90,92)	52.3	53.3	46.7	
Week 180 (n=88,90,92)	51.1	54.4	46.7	
Week 192 (n=88,90,92)	51.1	55.6	46.7	
Week 204 (n=88,90,92)	50	54.4	46.7	
Week 216 (n=88,90,92)	50	54.4	46.7	

Notes:

[2] - All participants with evaluable data at given time point.

[3] - All participants with evaluable data at given time point.

[4] - All participants with evaluable data at given time point.

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Clinical Response Per HiSCR at Each Visit

End point title	Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Clinical Response Per HiSCR at Each Visit[5]

End point description:

Clinical response per HiSCR defined as percent reduction from baseline of the prior phase 3 study in the abscess and inflammatory nodule ≥ 50% (AN50) with no increase in the abscess count and no increase in the draining fistula count. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits. n=number of participants at given time point.

End point type	Primary

End point timeframe:

Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive data were summarized for this endpoint per protocol.

End point values	PBO/EW/EW			
Subject group type	Subject analysis set			
Number of subjects analysed	115[6]			
Units: percentage of participants				
number (not applicable)				
Entry of Period B (n=115)	26.1			
Week 12 (n=114)	54.4			
Week 24 (n=114)	57.9			
Week 36 (n=114)	57			
Week 48 (n=114)	60.5			
Week 60 (n=114)	57			
Week 72 (n=114)	50			
Week 84 (n=114)	50			
Week 96 (n=114)	53.5			
Week 108 (n=114)	52.6			
Week 120 (n=114)	53.5			
Week 132 (n=114)	56.1			
Week 144 (n=114)	51.8			
Week 156 (n=114)	52.6			
Week 168 (n=114)	55.3			
Week 180 (n=114)	54.4			
Week 192 (n=114)	53.5			
Week 204 (n=114)	53.5			

Notes:

[6] - All participants with evaluable data at given time point.

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants in the PBO/PBO/EW Analysis Population Achieving Clinical Response Per HiSCR at Each Visit

End point title	Percentage of Participants in the PBO/PBO/EW Analysis Population Achieving Clinical Response Per HiSCR at Each Visit[7]

End point description:

Clinical response per HiSCR defined as percent reduction from baseline of the prior phase 3 study in the abscess and inflammatory nodule ≥ 50% (AN50) with no increase in the abscess count and no increase in the draining fistula count. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits. n=number of participants at given time point.

End point type	Primary

End point timeframe:

Entry of M12-555, Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive data were summarized for this endpoint per protocol.

End point values	PBO/PBO/EW			
Subject group type	Subject analysis set			
Number of subjects analysed	123[8]			
Units: percentage of participants				
number (not applicable)				
Entry of M12-555 (n=123)	19.5			
Week 4 (n=122)	46.7			
Week 8 (n=122)	51.6			
Week 12 (n=122)	48.4			
Week 18 (n=122)	57.4			
Week 24 (n=122)	55.7			
Week 36 (n=122)	60.7			
Week 48 (n=122)	54.9			
Week 60 (n=122)	55.7			
Week 72 (n=122)	54.9			
Week 84 (n=122)	54.9			
Week 96 (n=122)	57.4			
Week 108 (n=122)	54.9			
Week 120 (n=122)	52.5			
Week 132 (n=122)	54.1			
Week 144 (n=122)	51.6			
Week 156 (n=122)	50.8			
Week 168 (n=122)	51.6			
Week 180 (n=122)	51.6			
Week 192 (n=122)	51.6			

Notes:

[8] - All participants with evaluable data at given time point.

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants in the EW/EW/EW Analysis Population Who Achieved Abscess and Inflammatory Nodule (AN) Count of 0, 1, or 2 at Each Visit

End point title	Percentage of Participants in the EW/EW/EW Analysis Population Who Achieved Abscess and Inflammatory Nodule (AN) Count of 0, 1, or 2 at Each Visit[9]

End point description:

The percentage of participants with AN counts lowered to 0, 1, or 2 at each visit. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

End point type	Primary

End point timeframe:

Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive data were summarized for this endpoint per protocol.

End point values	EW/EW/EW			
Subject group type	Subject analysis set			
Number of subjects analysed	88[10]			
Units: percentage of participants				
number (not applicable)				
Week 2	22.7			
Week 4	28.4			
Week 8	38.6			
Week 12	35.2			
Week 16	37.5			
Week 20	42			
Week 24	36.4			
Week 36	48.9			
Week 48	46.6			
Week 60	43.2			
Week 72	50			
Week 84	45.5			
Week 96	44.3			
Week 108	46.6			
Week 120	44.3			
Week 132	44.3			
Week 144	43.2			
Week 156	45.5			
Week 168	46.6			
Week 180	46.6			
Week 192	47.7			
Week 204	47.7			
Week 216	46.6			

Notes:

[10] - All participants with evaluable data at given time point.

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Who Achieved AN Count of 0, 1, or 2 at Each Visit

End point title	Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Who Achieved AN Count of 0, 1, or 2 at Each Visit[11]

End point description:

The percentage of participants with AN counts lowered to 0, 1, or 2 at each visit. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits. n=number of participants at given time point.

End point type	Primary

End point timeframe:

Entry of M12-555, Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive data were summarized for this endpoint per protocol.

End point values	EW/EOW/EW	EW/PBO/EW	PBO/PBO/EW	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	90[12]	92[13]	123[14]	
Units: percentage of participants				
number (not applicable)				
Entry of M12-555 (n=90,92,123)	31.1	22.8	21.1	
Week 4 (n=87,92,122)	35.6	34.8	44.3	
Week 8 (n=88,92,122)	43.2	42.4	53.3	
Week 12 (n=88,92,122)	45.5	44.6	45.1	
Week 18 (n=88,92,122)	50	41.3	50	
Week 24 (n=88,92,122)	43.2	46.7	57.4	
Week 36 (n=88,92,122)	54.5	45.7	57.4	
Week 48 (n=88,92,122)	50	42.4	52.5	
Week 60 (n=88,92,122)	48.9	43.5	51.6	
Week 72 (n=88,92,122)	50	43.5	54.1	
Week 84 (n=88,92,122)	53.4	44.6	50.8	
Week 96 (n=88,92,122)	51.1	40.2	52.5	
Week 108 (n=88,92,122)	51.1	40.2	51.6	
Week 120 (n=88,92,122)	46.6	37	52.5	
Week 132 (n=88,92,122)	51.1	37	53.3	
Week 144 (n=88,92,122)	48.9	41.3	52.5	
Week 156 (n=88,92,122)	47.7	39.1	51.6	
Week 168 (n=88,92,122)	51.1	35.9	51.6	
Week 180 (n=88,92,122)	51.1	35.9	51.6	
Week 192 (n=88,92,122)	51.1	35.9	51.6	

Notes:

[12] - All participants with evaluable data at given time point.

[13] - All participants with evaluable data at given time point.

[14] - All participants with evaluable data at given time point.

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants in the PBO/EW/EW Analysis Population Who Achieved AN Count of 0, 1, or 2 at Each Visit

End point title	Percentage of Participants in the PBO/EW/EW Analysis Population Who Achieved AN Count of 0, 1, or 2 at Each Visit[15]

End point description:

The percentage of participants with AN counts lowered to 0, 1, or 2 at each visit. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits. n=number of participants at given time point.

End point type	Primary

End point timeframe:

Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204

Notes:

[15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive data were summarized for this endpoint per protocol.

End point values	PBO/EW/EW			
Subject group type	Subject analysis set			
Number of subjects analysed	115[16]			
Units: percentage of participants				
number (not applicable)				
Entry of Period B (n=115)	20			
Week 12 (n=114)	38.6			
Week 24 (n=114)	43			
Week 36 (n=114)	42.1			
Week 48 (n=114)	43.9			
Week 60 (n=114)	45.6			
Week 72 (n=114)	43.9			
Week 84 (n=114)	43.9			
Week 96 (n=114)	46.5			
Week 108 (n=114)	42.1			
Week 120 (n=114)	45.6			
Week 132 (n=114)	46.5			
Week 144 (n=114)	49.1			
Week 156 (n=114)	45.6			
Week 168 (n=114)	46.5			
Week 180 (n=114)	46.5			
Week 192 (n=114)	45.6			
Week 204 (n=114)	45.6			

Notes:

[16] - All participants with evaluable data at given time point.

Statistical analyses

No statistical analyses for this end point

Primary: Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the EW/EW/EW Analysis Population

End point title	Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the EW/EW/EW Analysis Population[17]

End point description:

The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; no-6 points). The total Sartorius score is the sum of the 12 regional scores. Higher scores indicate greater severity of HS. A negative change indicates decrease in severity. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

End point type	Primary

End point timeframe:

Baseline (in prior phase 3 study) to Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216

Notes:

[17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive data were summarized for this endpoint per protocol.

End point values	EW/EW/EW			
Subject group type	Subject analysis set			
Number of subjects analysed	88[18]			
Units: units on a scale				
arithmetic mean (standard deviation)				
Week 2	-18 (± 25.27)			
Week 4	-21 (± 31.81)			
Week 8	-22.8 (± 35.45)			
Week 12	-23.9 (± 48.3)			
Week 16	-26.6 (± 54.63)			
Week 20	-32.1 (± 73.69)			
Week 24	-36.6 (± 74.99)			
Week 36	-41.6 (± 93.11)			
Week 48	-42.2 (± 115.22)			
Week 60	-41.9 (± 119.98)			
Week 72	-43.2 (± 122.3)			
Week 84	-42.8 (± 123.18)			
Week 96	-43.2 (± 126.21)			
Week 108	-43.2 (± 124.92)			
Week 120	-43.4 (± 127.65)			
Week 132	-42.5 (± 128.45)			
Week 144	-42.4 (± 129.37)			
Week 156	-40.7 (± 130.3)			
Week 168	-41.5 (± 130.4)			
Week 180	-41.8 (± 129.89)			
Week 192	-41.9 (± 130.46)			
Week 204	-41.4 (± 130.72)			
Week 216	-41.4 (± 130.94)			

Notes:

[18] - All participants with evaluable data at given time point.

Statistical analyses

No statistical analyses for this end point

Primary: Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations

End point title	Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations[19]

End point description:

The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; no-6 points). The total Sartorius score is the sum of the 12 regional scores. Higher scores indicate greater severity of HS. A negative change indicates decrease in severity. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits. n=number of participants at given time point.

End point type	Primary

End point timeframe:

Baseline (in prior phase 3 study) to Entry of M12-555 and Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192

Notes:

[19] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive data were summarized for this endpoint per protocol.

End point values	EW/EOW/EW	EW/PBO/EW	PBO/PBO/EW	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	90[20]	92[21]	123[22]	
Units: units on a scale				
arithmetic mean (standard deviation)				
Entry of M12-555 (n=90,92,123)	-23.1 (± 56.94)	-10.5 (± 56.74)	0.2 (± 51.35)	
Week 4 (n=87,92,122)	-30.2 (± 48.99)	-18.8 (± 56.52)	-16.2 (± 56.16)	
Week 8 (n=88,92,122)	-34.9 (± 47.42)	-21.2 (± 63.26)	-24.8 (± 51.55)	
Week 12 (n=88,92,122)	-34.8 (± 55.71)	-25.5 (± 57.92)	-26.2 (± 54.58)	
Week 18 (n=88,92,122)	-35.9 (± 47.92)	-26.2 (± 60.59)	-32.3 (± 48.6)	
Week 24 (n=88,92,122)	-37.1 (± 47.39)	-24.1 (± 61.52)	-33.5 (± 50.2)	
Week 36 (n=88,92,122)	-37.1 (± 46.07)	-24.7 (± 63.81)	-33.6 (± 57.58)	
Week 48 (n=88,92,122)	-37.5 (± 47.94)	-24.8 (± 63.21)	-30.2 (± 64.84)	
Week 60 (n=88,92,122)	-34.8 (± 50.17)	-22.6 (± 65.06)	-31.7 (± 66.33)	
Week 72 (n=88,92,122)	-35.4 (± 55.22)	-20.1 (± 64.52)	-31.8 (± 65.26)	
Week 84 (n=88,92,122)	-36.6 (± 51.33)	-20 (± 66.02)	-29.5 (± 65.79)	
Week 96 (n=88,92,122)	-34 (± 49.42)	-18.3 (± 65.14)	-29 (± 68.85)	
Week 108 (n=88,92,122)	-34 (± 54.41)	-18.3 (± 66.88)	-28.4 (± 71.52)	
Week 120 (n=88,92,122)	-31.8 (± 60.85)	-16.2 (± 66.82)	-28.3 (± 70.37)	
Week 132 (n=88,92,122)	-35.1 (± 53.01)	-16.7 (± 66.87)	-28.8 (± 69.79)	
Week 144 (n=88,92,122)	-35.1 (± 53.94)	-16.6 (± 67.3)	-28.6 (± 70.03)	

Week 156 (n=88,92,122)	-34.7 (± 53.95)	-15.7 (± 67.09)	-28 (± 69.11)	
Week 168 (n=88,92,122)	-35.6 (± 53.72)	-15.5 (± 67.4)	-28.7 (± 69.81)	
Week 180 (n=88,92,122)	-35.6 (± 53.64)	-15.4 (± 67.39)	-28.7 (± 69.81)	
Week 192 (n=88,92,122)	-35.6 (± 53.64)	-15.4 (± 67.39)	-28.7 (± 69.81)	

Notes:

[20] - All participants with evaluable data at given time point.

[21] - All participants with evaluable data at given time point.

[22] - All participants with evaluable data at given time point.

Statistical analyses

No statistical analyses for this end point

Primary: Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the PBO/EW/EW Analysis Population

End point title	Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the PBO/EW/EW Analysis Population[23]

End point description:

The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; no-6 points). The total Sartorius score is the sum of the 12 regional scores. Higher scores indicate greater severity of HS. A negative change indicates decrease in severity. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits. n=number of participants at given time point.

End point type	Primary

End point timeframe:

Baseline (in prior phase 3 study) to Entry of Period B in prior phase 3 study and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204

Notes:

[23] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive data were summarized for this endpoint per protocol.

End point values	PBO/EW/EW			
Subject group type	Subject analysis set			
Number of subjects analysed	115[24]			
Units: units on a scale				
arithmetic mean (standard deviation)				
Entry of Period B (n=115)	-18 (± 38.32)			
Week 12 (n=114)	-43.2 (± 48.07)			
Week 24 (n=114)	-43 (± 53.08)			
Week 36 (n=114)	-49.5 (± 57.05)			
Week 48 (n=114)	-47.1 (± 61.95)			
Week 60 (n=114)	-46.2 (± 60.94)			
Week 72 (n=114)	-44.5 (± 67.13)			

Week 84 (n=114)	-46.8 (± 64.57)			
Week 96 (n=114)	-45.5 (± 70.63)			
Week 108 (n=114)	-45 (± 74.15)			
Week 120 (n=114)	-45.9 (± 75.3)			
Week 132 (n=114)	-44.4 (± 78.09)			
Week 144 (n=114)	-45.4 (± 76.53)			
Week 156 (n=114)	-46 (± 76.17)			
Week 168 (n=114)	-46.1 (± 75.84)			
Week 180 (n=114)	-45.8 (± 75.96)			
Week 192 (n=114)	-45.8 (± 75.89)			
Week 204 (n=114)	-45.9 (± 75.96)			

Notes:

[24] - All participants with evaluable data at given time point.

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants in the EW/EW/EW Analysis Population Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst ≥ 3

End point title	Percentage of Participants in the EW/EW/EW Analysis Population Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst ≥ 3[25]

End point description:

The Patient's Global Assessment of Skin Pain Numeric Rating Scale (NRS) was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the Patient's Global Assessment of Skin Pain (NRS30) - at worst at each visit among participants with baseline skin pain NRS - at worst ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

End point type	Primary

End point timeframe:

Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192

Notes:

[25] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive data were summarized for this endpoint per protocol.

End point values	EW/EW/EW			
Subject group type	Subject analysis set			
Number of subjects analysed	63[26]			
Units: percentage of participants				
number (not applicable)				
Week 2	47.6			
Week 4	46			
Week 8	44.4			
Week 12	42.9			
Week 16	46			
Week 20	50.8			
Week 24	54			
Week 36	58.7			
Week 48	54			
Week 60	52.4			
Week 72	54			
Week 84	52.4			
Week 96	49.2			
Week 108	54			
Week 120	50.8			
Week 132	46			
Week 144	54			
Week 156	52.4			
Week 168	52.4			
Week 180	52.4			
Week 192	52.4			

Notes:

[26] - All participants with baseline skin pain NRS-at worst ≥3 and with evaluable data at given time point

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst ≥ 3

End point title	Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst ≥ 3[27]

End point description:

The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - at worst at each visit among participants with baseline skin pain NRS - at worst ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits. n=number of participants at given time point.

End point type	Primary

End point timeframe:

Entry of M12-555, and Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192

Notes:

[27] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive data were summarized for this endpoint per protocol.

End point values	EW/EOW/EW	EW/PBO/EW	PBO/PBO/EW	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	65[28]	64[29]	84[30]	
Units: percentage of participants				
number (not applicable)				
Entry of M12-555 (n=65,64,84)	40	21.9	22.6	
Week 4 (n=61,58,83)	47.5	43.1	44.6	
Week 8 (n=62,63,83)	45.2	47.6	51.8	
Week 12 (n=63,63,83)	41.3	54	51.8	
Week 18 (n=63,63,83)	47.6	50.8	55.4	
Week 24 (n=63,63,83)	42.9	47.6	54.2	
Week 36 (n=63,63,83)	49.2	47.6	55.4	
Week 48 (n=63,63,83)	47.6	50.8	56.6	
Week 60 (n=63,63,83)	47.6	50.8	50.6	
Week 72 (n=63,63,83)	47.6	42.9	50.6	
Week 84 (n=63,63,83)	50.8	46	48.2	
Week 96 (n=63,63,83)	50.8	55.6	48.2	
Week 108 (n=63,63,83)	50.8	42.9	50.6	
Week 120 (n=63,63,83)	42.9	47.6	45.8	
Week 132 (n=63,63,83)	41.3	47.6	48.2	
Week 144 (n=63,63,83)	41.3	50.8	47	
Week 156 (n=63,63,83)	39.7	46	49.4	
Week 168 (n=63,63,83)	41.3	49.2	48.2	
Week 180 (n=63,63,83)	41.3	49.2	48.2	
Week 192 (n=63,63,83)	41.3	49.2	48.2	

Notes:

[28] - All participants with baseline skin pain NRS-at worst ≥3 and with evaluable data at given time point
[29] - All participants with baseline skin pain NRS-at worst ≥3 and with evaluable data at given time point
[30] - All participants with baseline skin pain NRS-at worst ≥3 and with evaluable data at given time point

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst ≥ 3

End point title	Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst ≥ 3[31]

End point description:

The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - at worst at each visit among participants with baseline skin pain NRS - at worst ≥ 3 are presented. Weekly averages of daily

assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits. n=number of participants at given time point.

End point type	Primary

End point timeframe:

Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204

Notes:

[31] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive data were summarized for this endpoint per protocol.

End point values	PBO/EW/EW			
Subject group type	Subject analysis set			
Number of subjects analysed	79[32]			
Units: percentage of participants				
number (not applicable)				
Entry of Period B (n=79)	31.6			
Week 12 (n=64)	51.6			
Week 24 (n=76)	55.3			
Week 36 (n=77)	55.8			
Week 48 (n=77)	53.2			
Week 60 (n=77)	58.4			
Week 72 (n=77)	64.9			
Week 84 (n=77)	63.6			
Week 96 (n=77)	62.3			
Week 108 (n=78)	55.1			
Week 120 (n=78)	56.4			
Week 132 (n=78)	53.8			
Week 144 (n=78)	55.1			
Week 156 (n=78)	51.3			
Week 168 (n=78)	57.7			
Week 180 (n=78)	57.7			
Week 192 (n=78)	56.4			
Week 204 (n=78)	57.7			

Notes:

[32] - All participants with baseline skin pain NRS-at worst ≥3 and with evaluable data at given time point

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants in the EW/EW/EW Analysis Population Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average ≥ 3

End point title	Percentage of Participants in the EW/EW/EW Analysis Population Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average ≥ 3[33]

End point description:

The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - on average at each visit

among participants with baseline skin pain NRS - on average ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

End point type	Primary

End point timeframe:

Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192

Notes:

[33] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive data were summarized for this endpoint per protocol.

End point values	EW/EW/EW			
Subject group type	Subject analysis set			
Number of subjects analysed	50[34]			
Units: percentage of participants				
number (not applicable)				
Week 2	56			
Week 4	52			
Week 8	48			
Week 12	46			
Week 16	40			
Week 20	50			
Week 24	46			
Week 36	58			
Week 48	56			
Week 60	56			
Week 72	56			
Week 84	56			
Week 96	54			
Week 108	50			
Week 120	48			
Week 132	56			
Week 144	56			
Week 156	58			
Week 168	56			
Week 180	56			
Week 192	56			

Notes:

[34] - All participants with baseline skin pain NRS-on average ≥3 with evaluable data at given time point

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average ≥ 3

End point title	Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average ≥ 3[35]

End point description:

The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - on average at each visit among participants with baseline skin pain NRS - on average ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits. n=number of participants at given time point.

End point type	Primary

End point timeframe:

Entry of M12-555, and Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192

Notes:

[35] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive data were summarized for this endpoint per protocol.

End point values	EW/EOW/EW	EW/PBO/EW	PBO/PBO/EW	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	55[36]	53[37]	69[38]	
Units: percentage of participants				
number (not applicable)				
Entry of M12-555 (n=55,53,69)	43.6	37.7	31.9	
Week 4 (n=51,47,68)	49	46.8	61.8	
Week 8 (n=52,52,68)	46.2	55.8	61.8	
Week 12 (n=53,52,68)	39.6	59.6	58.8	
Week 18 (n=53,52,68)	45.3	59.6	63.2	
Week 24 (n=53,52,68)	39.6	53.8	54.4	
Week 36 (n=53,52,68)	45.3	48.1	58.8	
Week 48 (n=53,52,68)	47.2	51.9	58.8	
Week 60 (n=53,52,68)	43.4	53.8	55.9	
Week 72 (n=53,52,68)	47.2	59.6	55.9	
Week 84 (n=53,52,68)	49.1	48.1	52.9	
Week 96 (n=53,52,68)	47.2	57.7	57.4	
Week 108 (n=53,52,68)	49.1	44.2	54.4	
Week 120 (n=53,52,68)	39.6	48.1	54.4	
Week 132 (n=53,52,68)	43.4	50	54.4	
Week 144 (n=53,52,68)	43.4	50	54.4	
Week 156 (n=53,52,68)	43.4	46.2	55.9	
Week 168 (n=53,52,68)	43.4	48.1	54.4	
Week 180 (n=53,52,68)	43.4	48.1	54.4	
Week 192 (n=53,52,68)	43.4	48.1	54.4	

Notes:

[36] - All participants with baseline skin pain NRS-on average ≥3 with evaluable data at given time point
[37] - All participants with baseline skin pain NRS-on average ≥3 with evaluable data at given time point
[38] - All participants with baseline skin pain NRS-on average ≥3 with evaluable data at given time point

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average ≥ 3

End point title	Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average ≥ 3[39]

End point description:

The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - on average at each visit among participants with baseline skin pain NRS - on average ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits. n=number of participants at given time point.

End point type	Primary

End point timeframe:

Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204

Notes:

[39] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive data were summarized for this endpoint per protocol.

End point values	PBO/EW/EW			
Subject group type	Subject analysis set			
Number of subjects analysed	62[40]			
Units: percentage of participants				
number (not applicable)				
Entry of Period B (n=62)	30.6			
Week 12 (n=49)	59.2			
Week 24 (n=59)	61			
Week 36 (n=60)	61.7			
Week 48 (n=60)	53.3			
Week 60 (n=60)	60			
Week 72 (n=60)	58.3			
Week 84 (n=60)	60			
Week 96 (n=60)	61.7			
Week 108 (n=61)	62.3			
Week 120 (n=61)	62.3			
Week 132 (n=61)	59			
Week 144 (n=61)	60.7			
Week 156 (n=61)	55.7			
Week 168 (n=61)	62.3			
Week 180 (n=61)	62.3			
Week 192 (n=61)	60.7			
Week 204 (n=61)	62.3			

Notes:

[40] - All participants with baseline skin pain NRS-on average ≥3 with evaluable data at given time point

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 70 days after the last dose of study drug (up to 225 weeks).

Adverse event reporting additional description:

TEAEs and TESAEs were defined as AEs and SAEs with an onset date on or after the first dose of adalimumab in either M12-555 or in prior studies M11-313 or M11-810, excluding AEs and SAEs with onset date during a protocol-defined treatment gap.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	19.0

Reporting groups

Reporting group title	All Adalimumab

Reporting group description:

Participants who received at least 1 dose of adalimumab (40 mg every week) in M12-555.

Serious adverse events	All Adalimumab		
Total subjects affected by serious adverse events			
subjects affected / exposed	99 / 508 (19.49%)		
number of deaths (all causes)	3		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer stage III			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac myxoma			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hodgkin's disease			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Invasive breast carcinoma			

subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Metastases to liver				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Pancreatic carcinoma				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	1 / 1			
Papillary cystadenoma lymphomatosum				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Seminoma				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Squamous cell carcinoma of skin				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Vascular disorders				
Deep vein thrombosis				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Hypertension				
subjects affected / exposed	2 / 508 (0.39%)			
occurrences causally related to treatment / all	1 / 2			
deaths causally related to treatment / all	0 / 0			
Hypertensive crisis				

subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Non-cardiac chest pain			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pyrexia			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Social circumstances			
Sexual abuse			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
Ovarian cyst			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pelvic prolapse			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Uterine cyst			

subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Dysfunctional uterine bleeding				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Respiratory, thoracic and mediastinal disorders				
Acute pulmonary oedema				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Acute respiratory failure				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pleurisy				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pneumonitis				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Respiratory distress				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Respiratory failure				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Psychiatric disorders				

Suicidal ideation				
subjects affected / exposed	2 / 508 (0.39%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Investigations				
Autoantibody positive				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Body temperature increased				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Injury, poisoning and procedural complications				
Accidental overdose				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Ankle fracture				
subjects affected / exposed	2 / 508 (0.39%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Burns second degree				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Contusion				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Foot fracture				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			

Joint injury			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lower limb fracture			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Meniscus injury			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Procedural dizziness			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Procedural nausea			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Procedural pain			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Radial head dislocation			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Scar			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Tendon rupture			

subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Upper limb fracture			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Congenital, familial and genetic disorders			
Odontogenic cyst			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	2 / 508 (0.39%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Cardiac arrest			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac failure			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Palpitations			
subjects affected / exposed	2 / 508 (0.39%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Coma hepatic				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Hemiplegia				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Transient ischaemic attack				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Blood and lymphatic system disorders				
Lymphadenitis				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal disorders				
Autoimmune pancreatitis				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Crohn's disease				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Incarcerated umbilical hernia				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Peritoneal cyst				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			

Hepatobiliary disorders			
Cholangitis			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cholelithiasis			
subjects affected / exposed	2 / 508 (0.39%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Cutis laxa			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hidradenitis			
subjects affected / exposed	29 / 508 (5.71%)		
occurrences causally related to treatment / all	1 / 39		
deaths causally related to treatment / all	0 / 0		
Pustular psoriasis			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Pyoderma gangrenosum			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Dermatitis contact			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Acute kidney injury			

subjects affected / exposed	2 / 508 (0.39%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Ureteric obstruction			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Intervertebral disc protrusion			
subjects affected / exposed	2 / 508 (0.39%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Joint instability			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Muscle spasms			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Appendicitis			
subjects affected / exposed	2 / 508 (0.39%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Cellulitis			
subjects affected / exposed	2 / 508 (0.39%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		

Erysipelas			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Groin abscess			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Infection			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Peritonitis			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Peritonsillar abscess			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Periumbilical abscess			
subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pilonidal cyst			
subjects affected / exposed	2 / 508 (0.39%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	3 / 508 (0.59%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	0 / 0		
Pneumonia chlamydial			

subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Pneumonia viral				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Postoperative wound infection				
subjects affected / exposed	2 / 508 (0.39%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Pyelonephritis				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Sepsis				
subjects affected / exposed	2 / 508 (0.39%)			
occurrences causally related to treatment / all	1 / 2			
deaths causally related to treatment / all	0 / 0			
Septic shock				
subjects affected / exposed	2 / 508 (0.39%)			
occurrences causally related to treatment / all	1 / 2			
deaths causally related to treatment / all	0 / 0			
Vulval abscess				
subjects affected / exposed	1 / 508 (0.20%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Metabolism and nutrition disorders				
Obesity				
subjects affected / exposed	3 / 508 (0.59%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Type 2 diabetes mellitus				

subjects affected / exposed	1 / 508 (0.20%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	All Adalimumab		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	349 / 508 (68.70%)		
Vascular disorders			
Hypertension			
subjects affected / exposed	28 / 508 (5.51%)		
occurrences (all)	31		
Nervous system disorders			
Headache			
subjects affected / exposed	80 / 508 (15.75%)		
occurrences (all)	149		
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	29 / 508 (5.71%)		
occurrences (all)	42		
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	33 / 508 (6.50%)		
occurrences (all)	36		
Nausea			
subjects affected / exposed	32 / 508 (6.30%)		
occurrences (all)	37		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	27 / 508 (5.31%)		
occurrences (all)	31		
Skin and subcutaneous tissue disorders			
Hidradenitis			
subjects affected / exposed	125 / 508 (24.61%)		
occurrences (all)	237		

Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	38 / 508 (7.48%)		
occurrences (all)	44		
Back pain			
subjects affected / exposed	33 / 508 (6.50%)		
occurrences (all)	41		
Infections and infestations			
Bronchitis			
subjects affected / exposed	37 / 508 (7.28%)		
occurrences (all)	48		
Gastroenteritis			
subjects affected / exposed	26 / 508 (5.12%)		
occurrences (all)	33		
Influenza			
subjects affected / exposed	40 / 508 (7.87%)		
occurrences (all)	58		
Nasopharyngitis			
subjects affected / exposed	92 / 508 (18.11%)		
occurrences (all)	172		
Sinusitis			
subjects affected / exposed	29 / 508 (5.71%)		
occurrences (all)	43		
Upper respiratory tract infection			
subjects affected / exposed	84 / 508 (16.54%)		
occurrences (all)	140		
Urinary tract infection			
subjects affected / exposed	40 / 508 (7.87%)		
occurrences (all)	49		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
11 October 2012	The main purpose of this amendment was to add pharmacokinetic adalimumab concentration and anti-adalimumab antibody (AAA) assays to some study visits, and update phase 2 safety and efficacy information in the background section.
07 August 2013	The main purpose of this amendment was to add new safety monitoring language, incorporate new CDC guidelines on TB screening, add additional prohibited therapy (recently approved biologic therapies), add biomarker time points at weeks 12 and 48 visits, and add collection of information regarding surgery performed for chronic hidradenitis suppurativa (HS).

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported